These authors did their work as part of their roles at the European Organisation for Research and Treatment of Cancer headquarters, which have since ended.
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results